Bioceres Reports Fiscal Fourth Quarter and Full-Year 2025 Results

Key Takeaways

• Bioceres reported Q4 revenue of $74.7 million, down 40% year-over-year.
• Full-year revenue totaled $335.3 million, a 28% decline compared to FY24.
• Gross profit for FY25 was $131.7 million, with margins stable at 39%.
• Net loss was $48.0 million in Q4 and $55.2 million for the year.
• Adjusted EBITDA was negative $4.5 million in Q4 but positive $28.3 million for FY25.

Bioceres Financial Performance in Q4 2025

Bioceres reported total revenue of $74.7 million in the fourth quarter of fiscal 2025, a 40% decline compared to the same period last year. The drop was primarily due to weaker demand in Argentina and lower HB4-related sales. Gross profit for the quarter was $25.2 million, down 47% year-over-year, while gross margin contracted from 38% to 34%.

The company recorded an operating loss of $14.9 million, a net loss of $48.0 million, and an Adjusted EBITDA of negative $4.5 million.

Full-Year 2025 Results

For the fiscal year ended June 30, 2025, Bioceres posted total revenue of $335.3 million, a 28% decrease from FY24. Gross profit was $131.7 million, down 29% from the prior year, although gross margin remained stable at 39%.

The company reported an operating loss of $3.7 million, a net loss of $55.2 million, and Adjusted EBITDA of $28.3 million, reflecting the impact of revenue declines across all major business segments.

Net cash flow from operating activities reached $53.0 million for the year, a 27% improvement compared to FY24, underscoring the company’s focus on cash discipline despite lower profitability.

Bioceres’ CEO Commentary

“We are reporting a disappointing final quarter to an extremely challenging fiscal year,” said Federico Trucco, Chief Executive Officer of Bioceres. “Our results this quarter were significantly impacted by the shift in our seed business strategy, which alone accounted for close to half of the gross margin decline. While this impact was anticipated and carries positive implications for our business going forward, the persistent slowdown in Argentina and a higher-than-normal level of impairments also weighed on performance.”

Trucco added that Bioceres has accelerated adjustments to its cost structure, targeting operating expense savings of 10–12%, and has reduced incremental CAPEX and R&D investment by 50% for fiscal years 2026 and 2027.

Outlook and Strategic Priorities

Bioceres expects current market conditions in Argentina to normalize in the coming months. The company has extended its convertible note maturities under amended terms, restructured its board, and is searching for a new Chief Financial Officer following leadership changes.

With key product registrations and manufacturing capacity already in place, Bioceres believes its near-term growth strategy remains on track despite reduced investment levels.

Read the full report here.